This was followed by a joint Commission and EMEA meeting in November 1997 at the EMEA attended by representatives of the drug regulatory authorities of Bulgaria, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, the Slovak Republic and Slovenia.